Histogen Inc. (HSTO) News

Histogen Inc. (HSTO): $0.21

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add HSTO to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#122 of 381

in industry

Filter HSTO News Items

HSTO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest HSTO News From Around the Web

Below are the latest news stories about HISTOGEN INC that investors may wish to consider to help them evaluate HSTO as an investment opportunity.

Histogen to Explore Strategic Alternatives

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today announced that it has completed a review of its business, including the status of programs, resources and capabilities, and has decided to pause further development of its programs

Yahoo | July 5, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Pre-market stock movers are a hot topic with traders on Thursday as we go over the shares seeing the biggest movements this morning.

William White on InvestorPlace | June 8, 2023

Histogen Reports First Quarter 2023 Results and Provides Business Update

Received FDA Clearance of IND Application for Emricasan for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Signed Exclusive Intellectual Property License Agreement with Johns Hopkins University Steven J. Mento Ph.D. Appointed President and CEO SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potentia

Yahoo | May 11, 2023

Histogen Announces Online Publication in the Journal of Investigative Dermatology

Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today

Yahoo | April 20, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders need to know about this morning!

William White on InvestorPlace | April 5, 2023

Histogen Announces Exclusive Intellectual Property License Agreement with Johns Hopkins University

Licensed Patents Expected to Provide Freedom to Operate and Exclusivity for Emricasan Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, April 03, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, toda

Yahoo | April 3, 2023

Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use

The Newly Issued Patent is Expected to Provide Protection into 2040 Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today announced that t

Yahoo | March 16, 2023

Histogen Reports Year-End 2022 Results and Provides Business Update

Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory DiseasesSAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today reported financial results for the year ended December 31, 2022, and provided an upda

Yahoo | March 9, 2023

Histogen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments for infectious and inflammatory diseases and has a pipeline of restorative therapeutics for orthopedic indications, today announced the Board of Directors, upon the recommendation of the Company’s Compensation Committee granted Alfred J. Spada, the company’s recently appointed Executive Vice President

Yahoo | February 27, 2023

Histogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer

Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory DiseasesSAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments for infectious and inflammatory diseases and has a pipeline of restorative therapeutics for orthopedic indications, today announced the appointment of Alfred P. Spada Ph.D. as Executive Vice Presiden

Yahoo | January 3, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!